Saurabh Zanwar, Assistant Professor at Mayo Clinic, shared a post on X:
“Sharing some exciting data today at ASH25 poster sessions:
#3940: Single-cell transcriptomic profiling of extramedullary disease reveals a distinctly aggressive biology, marked by highly proliferative, predominantly MYC-driven states with strong enrichment of EMT programs.
This is coupled with suppression of oxidative phosphorylation and broad dampening of key immune signaling pathways.
We also observe striking upregulation of CD44, ACTN4, and angiogenesis-related genes, alongside pronounced heterogeneity in therapeutic target expression—underscoring both the biological plasticity and therapeutic challenge of EMD.
#3540: High-resolution WES across WM disease states reveals TP53 and MAP3K14 alterations accumulating at relapse.
Distinct CNA patterns, including BCL6 gains and strong signal of non-canonical MAPK activity in relapsed WM, define treatment-exposed and high-risk biology.
#4069: On behalf of the US MM immunotherapy consortium, likely the largest yet collated series of patients with RRMM (n =943) treated with bispecific antibodies.
Some very interesting data on early treatment failures and exposure to prior BCMA agents.”
More updates from ASH25.